DC
Therapeutic Areas
Biophytis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BIO101 (20-hydroxyecdysone) | Sarcopenia | Phase 3 |
| MASSIVE Project Candidates | Sarcopenia (Next-generation) | Discovery |
| AI Platform Candidates | Dry Age-Related Macular Degeneration (AMD) | Discovery |
Leadership Team at Biophytis
SV
Stanislas Veillet
Chairman & Chief Executive Officer
EB
Edouard Bieth
Chief Strategy Officer
CB
Chiara Baccelli
Director of Pharmaceutical Operations and Quality Assurance
CC
Christophe Courtillat
Chief Financial Officer
PJ
Pierre J. Dilda
Chief Scientific Officer
WD
Waly Dioh
Chief Operating Officer
PJ
Pr. Jean Mariani
Chief Medical Officer
CA
Claude Allary
Board of Directors
NC
Nadine Coulm
Board of Directors
PR
Pr. Roger A. Fielding
Scientific Advisory Board